Lataa...
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. For patients with unresectable or metastatic HCC, conventional chemotherapy is of limited or no benefit. Sorafenib is the only systemic treatment to demonstrate a s...
Tallennettuna:
| Julkaisussa: | World J Hepatol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Baishideng Publishing Group Inc
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404384/ https://ncbi.nlm.nih.gov/pubmed/25914779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i5.787 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|